PMID- 23581795
OWN - NLM
STAT- MEDLINE
DCOM- 20141208
LR  - 20140422
IS  - 1468-3083 (Electronic)
IS  - 0926-9959 (Linking)
VI  - 28
IP  - 5
DP  - 2014 May
TI  - Consensus recommendations for the treatment of basal cell carcinomas in Gorlin 
      syndrome with topical methylaminolaevulinate-photodynamic therapy.
PG  - 626-32
LID - 10.1111/jdv.12150 [doi]
AB  - BACKGROUND: Patients with Gorlin syndrome develop multiple basal cell carcinomas 
      (BCC), for which treatment is often difficult. Methylaminolevulinate-photodynamic 
      therapy (MAL-PDT) is approved for the treatment of superficial and nodular BCCs 
      in Canada and several European countries. OBJECTIVES: To establish consensus 
      recommendations for the use of MAL-PDT in patients with Gorlin syndrome. METHODS: 
      The Gorlin consensus panel was comprised of 7 dermatologists who had treated a 
      total of 83 patients with Gorlin syndrome using MAL-PDT. Consensus was developed 
      based on the personal experience of the expert and results of literature review 
      (on PUBMED using the keywords 'MAL' and 'PDT' and 'Gorlin' or 'naevoid basal cell 
      carcinoma syndrome'). RESULTS: Consensus was reached among the experts and the 
      literature review identified 9 relevant reports. The experts considered MAL-PDT a 
      generally effective and safe therapy for treatment of BCC in Gorlin syndrome. For 
      superficial BCC (sBCC), all sizes can be treated, and in nodular BCC (nBCC), 
      better efficacy can be achieved in thinner lesions (<2 mm in thickness). MAL-PDT 
      treatment schedule should be performed according to labelling although in 
      individual cases, it may be adapted and performed on a monthly basis based on 
      clinical assessment. Follow-up should be related to frequency of recurrence, and 
      severity, number and location of lesions. Multiple lesions and large areas may be 
      treated during the same session; however, adequate pain management should be 
      considered. CONCLUSIONS: MAL-PDT is safe and effective in patients with Gorlin 
      syndrome. Utilization of these recommendations may improve efficacy and clearance 
      rates in this population.
CI  - (c) 2013 The Authors Journal of the European Academy of Dermatology and Venereology 
      (c) 2013 European Academy of Dermatology and Venereology.
FAU - Basset-Seguin, N
AU  - Basset-Seguin N
AD  - Hopital Saint-Louis, Paris, France.
FAU - Bissonnette, R
AU  - Bissonnette R
FAU - Girard, C
AU  - Girard C
FAU - Haedersdal, M
AU  - Haedersdal M
FAU - Lear, J T
AU  - Lear JT
FAU - Paul, C
AU  - Paul C
FAU - Piaserico, S
AU  - Piaserico S
LA  - eng
PT  - Journal Article
DEP - 20130413
PL  - England
TA  - J Eur Acad Dermatol Venereol
JT  - Journal of the European Academy of Dermatology and Venereology : JEADV
JID - 9216037
RN  - 88755TAZ87 (Aminolevulinic Acid)
SB  - IM
MH  - Administration, Topical
MH  - Adult
MH  - Aged
MH  - Aminolevulinic Acid/administration & dosage/*therapeutic use
MH  - Basal Cell Nevus Syndrome/*complications
MH  - Carcinoma, Basal Cell/complications/*drug therapy
MH  - Child
MH  - *Consensus
MH  - Humans
MH  - Middle Aged
MH  - Pain Management
MH  - *Photochemotherapy/adverse effects
MH  - Skin Neoplasms/complications/*drug therapy
EDAT- 2013/04/16 06:00
MHDA- 2014/12/15 06:00
CRDT- 2013/04/16 06:00
PHST- 2012/11/19 00:00 [received]
PHST- 2013/03/06 00:00 [accepted]
PHST- 2013/04/16 06:00 [entrez]
PHST- 2013/04/16 06:00 [pubmed]
PHST- 2014/12/15 06:00 [medline]
AID - 10.1111/jdv.12150 [doi]
PST - ppublish
SO  - J Eur Acad Dermatol Venereol. 2014 May;28(5):626-32. doi: 10.1111/jdv.12150. Epub 
      2013 Apr 13.